GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coeptis Therapeutics Holdings Inc (NAS:COEP) » Definitions » Deferred Tax

Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) Deferred Tax : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Coeptis Therapeutics Holdings Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Coeptis Therapeutics Holdings's change in deferred tax for the three months ended in Mar. 2024 was $0.00 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.


Coeptis Therapeutics Holdings Deferred Tax Historical Data

The historical data trend for Coeptis Therapeutics Holdings's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coeptis Therapeutics Holdings Deferred Tax Chart

Coeptis Therapeutics Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Deferred Tax
- - - -

Coeptis Therapeutics Holdings Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Coeptis Therapeutics Holdings Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Coeptis Therapeutics Holdings Deferred Tax Related Terms

Thank you for viewing the detailed overview of Coeptis Therapeutics Holdings's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.


Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
105 Bradford Road, Suite 420, Wexford, PA, USA, 15090
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio comprises multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
Executives
Tara Desilva director 105 BRADFORD RD., SUITE 420, WEXFORD PA 15090
David Mehalick director, 10 percent owner, officer: CEO and President 5000 TRESSDALE DRIVE, GIBSONIA PA 15044
Christopher P. Cochran director 105 BRADFORD RD., SUITE 420, WEXFORD PA 15090
Gene Salkind director 1165 WRACK ROAD, MEADOWBROOK PA 19046
Daniel Alexander Yerace director, officer: VP of Operations 402 SCHOMBURG COURT, CRANBERRY TOWNSHIP PA 16066
Chris Calise director, 10 percent owner, officer: Chief Financial Officer 801 S. POINTE DRIVE SUITE TH-1, MIAMI BEACH FL 33139
Philippe Deschamps director 105 BRADFORD RD, SUITE 420, WEXFORD PA 15090
Christine Elise Sheehy officer: CFO and Secretary 206 TAMARACK DRIVE, MARS PA 16046
Harraden Circle Investments, Llc 10 percent owner 299 PARK AVE, 21ST FLOOR, NEW YORK NY 10171
Harraden Circle Investors Gp, Lp 10 percent owner 299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171
Harraden Circle Investors Gp, Llc 10 percent owner 299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171
Fortmiller Frederick Vincent Jr. 10 percent owner 151 LULL ROAD, NEW BOSTON NH 03070
Harraden Circle Investors, Lp 10 percent owner 299 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10171
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Paul J Glazer 10 percent owner 250 WEST 55TH ST, SUITE 30A, NEW YORK NY 10019

Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) Headlines

From GuruFocus

Top 5 4th Quarter Trades of WEST CHESTER CAPITAL ADVISORS, INC

By GuruFocus Research GuruFocus Editor 02-06-2023